To co-develop and co-commercialize MK-6070, an investigational delta-like ligand 3 (DLL3) targeting T-cell engager, worldwide except for Japan where Merck retains exclusive rights
Dr. Vinod Kumar Paul highlighted the huge gap between the demand for and supply of organs
Approval is based on data from two Phase III studies in branch and central retinal vein occlusion (RVO) showing early and sustained vision improvements non-inferior to aflibercept
Nelarabine is a nucleoside metabolic inhibitor indicated for the treatment of patients with T-cell acute lymphoblastic leukemia
More emphasis should be given on investing healthcare resources towards prevention of diseases rather than only focusing on diagnostic and therapeutic options
The New Drug Application (NDA) includes data from the Phase III studies OASIS 1, 2 and 3 - showing elinzanetant significantly reduced the frequency and severity of moderate to severe vasomotor symptoms over 12 weeks compared to placebo
Dr. Reddy's had previously received the EU GMP certificate for its Rituximab drug substance
Report highlights significant improvements in adolescent well-being in India
Reported profit after tax declined 19% year-on-year to Rs 76 crores
Subscribe To Our Newsletter & Stay Updated
